Alector, Inc. (ALEC)
NASDAQ: ALEC · Real-Time Price · USD
2.160
+0.110 (5.37%)
At close: May 12, 2026, 4:00 PM EDT
2.160
0.00 (0.00%)
After-hours: May 12, 2026, 4:04 PM EDT
Alector Revenue
Alector had revenue of $1.05M in the quarter ending March 31, 2026, a decrease of -71.53%. This brings the company's revenue in the last twelve months to $18.42M, down -79.15% year-over-year. In the year 2025, Alector had annual revenue of $21.05M, down -79.07%.
Revenue (ttm)
$18.42M
Revenue Growth
-79.15%
P/S Ratio
12.54
Revenue / Employee
$178,806
Employees
103
Market Cap
239.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.05M | -79.51M | -79.07% |
| Dec 31, 2024 | 100.56M | 3.50M | 3.60% |
| Dec 31, 2023 | 97.06M | -36.56M | -27.36% |
| Dec 31, 2022 | 133.62M | -73.47M | -35.48% |
| Dec 31, 2021 | 207.09M | 185.99M | 881.54% |
| Dec 31, 2020 | 21.10M | -121.00K | -0.57% |
| Dec 31, 2019 | 21.22M | -6.46M | -23.33% |
| Dec 31, 2018 | 27.68M | 23.94M | 641.02% |
| Dec 31, 2017 | 3.74M | 3.32M | 797.84% |
| Dec 31, 2016 | 416.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Keros Therapeutics | 244.06M |
| Codexis | 78.09M |
| Orchestra BioMed Holdings | 33.48M |
| OmniAb | 28.94M |
| Sol-Gel Technologies | 19.39M |
| Camp4 Therapeutics | 3.93M |
| Humacyte | 2.04M |
| Milestone Pharmaceuticals | 1.55M |
ALEC News
- 4 days ago - Alector reports Q1 EPS (21c), consensus (28c) - TheFly
- 5 days ago - Alector Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 8 days ago - Alector price target raised to $2 from 90c at Morgan Stanley - TheFly
- 12 days ago - Alector to discontinue PROGRESS-AD trial of nivisnebart - TheFly
- 13 days ago - Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis - GlobeNewsWire
- 27 days ago - Alector upgraded to Overweight from Neutral at Cantor Fitzgerald - TheFly
- 2 months ago - Alector files $400M mixed securities shelf - TheFly
- 2 months ago - BTIG upgrades Alector to Buy on shift to novel therapeutics - TheFly